Table 1 Characteristics of product sample
From: Evaluating the administration costs of biologic drugs: development of a cost algorithm
Product name | Product type | Clinical indication considered | Disease type |
|---|---|---|---|
Biologics given intravenously | |||
Basiliximab†, Simulect® | mAb | Prophylaxis of acute organ rejection in allogeneic renal transplantation. | Acute |
Bevacizumab, Avastin® | mAb | First-line treatment of adult patients with non-small cell lung cancer. | Chronic |
Cetuximab, Erbitux® | mAb | Treatment of epidermal-growth-factor-receptor (EGFR)-expressing, Kirsten Rat Sarcoma-2 (KRAS) wild-type metastatic colorectal cancer. | Chronic |
Infliximab, Remicade® | mAb | Treatment of active rheumatoid arthritis that is unresponsive to disease modifying anti-rheumatic drugs (DMARDs) or those with severe active disease not previously treated with methotrexate (MTX) or DMARDs. | Chronic |
Oftamumab†,, Arzerra® | mAb | Treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab. | Chronic |
Panitumumab, Vectibix® | mAb | Treatment of wild-type KRAS metastatic colorectal cancer. | Chronic |
Tocilizumab, Actemra® | mAb | Treatment of moderate-to-severe active rheumatoid arthritis. | Chronic |
Trastuzumab, Herceptin® | mAb | Treatment of advanced and metastatic breast cancer. | Chronic |
Biologics given subcutaneously | |||
Adalimumab†, Humira® | mAb | Treatment of moderate-to-severely active Crohn's disease in children. | Chronic |
Canakinumab†, Ilaris® | mAb | Treatment of cryopyrin-associated periodic syndromes (CAPS) in adults. | Chronic |
Certolizumab pegol†, Cimzia® | fAb | Treatment of moderate-to-severe active rheumatoid arthritis in adults when response to DMARDs including MTX has been inadequate. | Chronic |
Denosumab†, Prolia® | mAb | Treatment of osteoporosis in post-menopausal women at increased risk of fractures. | Chronic |
Etanercept†, Enbrel® | Fusion protein | Treatment of active and progressive psoriatic arthritis that has not responded adequately to DMARDs. | Chronic |
Golimumab†, Simponi® | mAb | Treatment of moderate-to-severe active ankylosing spondylitis. | Chronic |
Omalizumab†, Xolair® | mAb | Management of immunoglobulin-E mediated asthma. | Chronic |
Ustekinumab†, Stelara® | mAb | Treatment of moderate-to-severe plaque psoriasis. | Chronic |
Biologics given intramuscularly | |||
Palivizumab†, Synagis® | mAb | Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. | Acute |
Interferon beta-1a†, Avonex® | Interferon protein | Treatment of relapsing multiple sclerosis in adult patients, i.e., two or more acute exacerbations in the previous three years without evidence of progressive disease. | Chronic |